Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128632 | 0.88 | TRPV1 (0.51) | TRPV1GAKALKTGFBR1RIPK2 | |
| SCHEMBL5117433 | 0.88 | TRPV1 (0.66) | TRPV1GAKALKTGFBR1RIPK2 | |
| SCHEMBL5120843 | 0.84 | TRPV1 (0.49) | TRPV1GAKALKTGFBR1RIPK2 | |
| SCHEMBL5118647 | 0.83 | TRPV1 (0.42) | TRPV1GAKALKTGFBR1RIPK2 | |
| SCHEMBL1863072 | 0.81 | TRPV1 (0.57) | TRPV1GAKALKTGFBR1RIPK2 | |
| SCHEMBL1861672 | 0.80 | TRPV1 (0.56) | TRPV1GAKALKTGFBR1 | |
| SCHEMBL5929308 | 0.80 | HTR1A (0.52) | TRPV1GAKTGFBR1RIPK2KDR | |
| SCHEMBL5122114 | 0.79 | TRPV1 (0.50) | TRPV1GAKALKTGFBR1RIPK2 | |
| SCHEMBL5929330 | 0.78 | GAK (0.57) | TRPV1GAKTGFBR1RIPK2KDR | |
| SCHEMBL12629696 | 0.78 | TRPV1 (0.49) | TRPV1GAKALKTGFBR1RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | PIGS, GPR52, GPR174 | TRPV1 477/4885GAK 3214/4885ALK 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.